Alzheimer’s Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC)

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 Study) (Cognition, FLAIR, PET)
Adult Changes in Thought (ACT) (Neuropathology, Cognition)
Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Vascular Risk Factors, Cognition, Fluid Biomarkers, DTI, FLAIR, MRI, PET)
Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) (Vascular Risk Factors, Cognition)
Memory & Aging Project at Knight Alzheimer’s Disease Research Center (MAP at Knight ADRC) (Cognition, Fluid Biomarkers)
Minority Aging Research Study (MARS) (Neuropathology, Vascular Risk Factors, Cognition, DTI, MRI)
National Alzheimer’s Coordinating Center (NACC) (Cognition, Fluid Biomarker, Neuropathology)
National Institute on Aging Alzheimer’s Disease Family Based Study (NIA-AD FBS) (Neuropathology, Vascular Risk Factors, Cognition)
Religious Orders Study/Memory and Aging Project (ROS, MAP – Rush) (Neuropathology, Vascular Risk Factors, Cognition, DTI, MRI)
Washington Heights/Inwood Columbia Aging Project (WHICAP) (Vascular Risk Factors, Cognition, FLAIR, MR)
Wisconsin Registry for Alzheimer’s Prevention (WRAP) (Vascular Risk Factors, Cognition, DTI, MRI, PET)

PAR-20-099 Harmonization of Alzheimer’s Disease and Related Dementias (AD/ADRD), (U24)

• Alzheimer’s Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC), U24-AG074855; MPI: Timothy J. Hohman, Michael Cuccaro, Arthur Toga; Project Period: September 30, 2021 – August 31, 2026

The ADSP Phenotype Harmonization Consortium (ADSP-PHC) is funded by NIA (U24 AG074855, U01 AG068057 and R01 AG059716). The harmonized cohorts within the ADSP-PHC include: the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 Study), a secondary prevention trial in preclinical Alzheimer’s disease, aiming to slow cognitive decline associated with brain amyloid accumulation in clinically normal older individuals. The A4 Study is funded by a public-private-philanthropic partnership, including funding from the National Institutes of Health-National Institute on Aging, Eli Lilly and Company, Alzheimer’s Association, Accelerating Medicines Partnership, GHR Foundation, an anonymous foundation and additional private donors, with in-kind support from Avid and Cogstate. The companion observational Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study is funded by the Alzheimer’s Association and GHR Foundation. The A4 and LEARN Studies are led by Dr. Reisa Sperling at Brigham and Women’s Hospital, Harvard Medical School and Dr. Paul Aisen at the Alzheimer’s Therapeutic Research Institute (ATRI), University of Southern California. The A4 and LEARN Studies are coordinated by ATRI at the University of Southern California, and the data are made available through the Laboratory for Neuro Imaging at the University of Southern California. The participants screening for the A4 Study provided permission to share their de-identified data in order to advance the quest to find a successful treatment for Alzheimer’s disease. We would like to acknowledge the dedication of all the participants, the site personnel, and all of the partnership team members who continue to make the A4 and LEARN Studies possible. The complete A4 Study Team list is available on: a4study.org/a4-study-team.; the Adult Changes in Thought study (ACT), U01 AG006781, U19 AG066567; Alzheimer’s Disease Neuroimaging Initiative (ADNI): Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California; Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA): 5R37AG015473, RF1AG015473, R56AG051876; Memory & Aging Project at Knight Alzheimer’s Disease Research Center (MAP at Knight ADRC): The Memory and Aging Project at the Knight-ADRC (Knight-ADRC). This work was supported by the National Institutes of Health (NIH) grants R01AG064614, R01AG044546, RF1AG053303, RF1AG058501, U01AG058922 and R01AG064877 to Carlos Cruchaga. The recruitment and clinical characterization of research participants at Washington University was supported by NIH grants P30AG066444, P01AG03991, and P01AG026276. Data collection and sharing for this project was supported by NIH grants RF1AG054080, P30AG066462, R01AG064614 and U01AG052410. We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine; National Alzheimer’s Coordinating Center (NACC): The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD); National Institute on Aging Alzheimer’s Disease Family Based Study (NIA-AD FBS): U24 AG056270; Religious Orders Study (ROS): P30AG10161,R01AG15819, R01AG42210; Memory and Aging Project (MAP – Rush): R01AG017917, R01AG42210; Minority Aging Research Study (MARS): R01AG22018, R01AG42210; Washington Heights/Inwood Columbia Aging Project (WHICAP): RF1 AG054023;and Wisconsin Registry for Alzheimer’s Prevention (WRAP): R01AG027161 and R01AG054047. Additional acknowledgments include the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS, U24AG041689) at the University of Pennsylvania, funded by NIA.  

1. Brenowitz, W. D., Fornage, M., Launer, L. J., Habes, M., Davatzikos, C., & Yaffe, K. (2023). Alzheimer’s Disease Genetic Risk, Cognition, and Brain Aging in Midlife. Annals of Neurology, 93(3), 629–634. https://doi.org/10.1002/ana.26569
2. Charisis, S., Rashid, T., Liu, H., Ware, J. B., Jensen, P. N., Austin, T. R., Li, K., Fadaee, E., Hilal, S., Chen, C., Hughes, T. M., Romero, J. R., Toledo, J. B., Longstreth, W. T., Hohman, T. J., Nasrallah, I., Bryan, R. N., Launer, L. J., Davatzikos, C., … Habes, M. (2023). Assessment of Risk Factors and Clinical Importance of Enlarged Perivascular Spaces by Whole-Brain Investigation in the Multi-Ethnic Study of Atherosclerosis. JAMA Network Open, 6(4), e239196. https://doi.org/10.1001/jamanetworkopen.2023.9196
3. Eissman, J. M., Wells, G., Khan, O. A., Liu, D., Petyuk, V. A., Gifford, K. A., Dumitrescu, L., Jefferson, A. L., & Hohman, T. J. (2023). Polygenic resilience score may be sensitive to preclinical Alzheimer’s disease changes. Pacific Symposium on Biocomputing, 28, 449–460
4. Evans, T. E., Knol, M. J., Schwingenschuh, P., Wittfeld, K., Hilal, S., Ikram, M. A., Dubost, F., van Wijnen, K. M. H., Katschnig, P., Yilmaz, P., de Bruijne, M., Habes, M., Chen, C., Langer, S., Völzke, H., Ikram, M. K., Grabe, H. J., Schmidt, R., Adams, H. H. H., & Vernooij, M. W. (2023). Determinants of Perivascular Spaces in the General Population: A Pooled Cohort Analysis of Individual Participant Data. Neurology, 100(2), e107–e122. https://doi.org/10.1212/WNL.0000000000201349
5. Hampton, O. L., Mukherjee, S., Properzi, M. J., Schultz, A. P., Crane, P. K., Gibbons, L. E., Hohman, T. J., Maruff, P., Lim, Y. Y., Amariglio, R. E., Papp, K. V., Johnson, K. A., Rentz, D. M., Sperling, R. A., & Buckley, R. F. (2023). Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies. Neuropsychology, 37(4), 436–449. https://doi.org/10.1037/neu0000833
6. Kang, M., Ang, T. F. A., Devine, S. A., Sherva, R., Mukherjee, S., Trittschuh, E. H., Gibbons, L. E., Scollard, P., Lee, M., Choi, S.-E., Klinedinst, B., Nakano, C., Dumitrescu, L. C., Durant, A., Hohman, T. J., Cuccaro, M. L., Saykin, A. J., Kukull, W. A., Bennett, D. A., … Farrer, L. A. (2023). A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores. Molecular Neurodegeneration, 18(1), 40. https://doi.org/10.1186/s13024-023-00633-4
7. Klingenberg, M., Stark, D., Eitel, F., Budding, C., Habes, M., Ritter, K., & Alzheimer’s Disease Neuroimaging Initiative. (2023). Higher performance for women than men in MRI-based Alzheimer’s disease detection. Alzheimer’s Research & Therapy, 15(1), 84. https://doi.org/10.1186/s13195-023-01225-6
8. Mukherjee, S., Choi, S.-E., Lee, M. L., Scollard, P., Trittschuh, E. H., Mez, J., Saykin, A. J., Gibbons, L. E., Sanders, R. E., Zaman, A. F., Teylan, M. A., Kukull, W. A., Barnes, L. L., Bennett, D. A., Lacroix, A. Z., Larson, E. B., Cuccaro, M., Mercado, S., Dumitrescu, L., … Crane, P. K. (2023). Cognitive domain harmonization and cocalibration in studies of older adults. Neuropsychology, 37(4), 409–423. https://doi.org/10.1037/neu0000835
9. Rashid, T., Li, K., Toledo, J. B., Nasrallah, I., Pajewski, N. M., Dolui, S., Detre, J., Wolk, D. A., Liu, H., Heckbert, S. R., Bryan, R. N., Williamson, J., Davatzikos, C., Seshadri, S., Launer, L. J., & Habes, M. (2023). Association of Intensive vs Standard Blood Pressure Control With Regional Changes in Cerebral Small Vessel Disease Biomarkers: Post Hoc Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Network Open, 6(3), e231055. https://doi.org/10.1001/jamanetworkopen.2023.1055
10. Toledo, J. B., Rashid, T., Liu, H., Launer, L., Shaw, L. M., Heckbert, S. R., Weiner, M., Seshadri, S., Habes, M., & Alzheimer’s Disease Neuroimaging Initiative. (2022). SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline. PloS One, 17(11), e0276392. https://doi.org/10.1371/journal.pone.0276392
11. Tosun, D., Thropp, P., Southekal, S., Spottiswoode, B., Fahmi, R., & Alzheimer’s Disease Neuroimaging Initiative. (2023). Profiling and predicting distinct tau progression patterns: An unsupervised data-driven approach to flortaucipir positron emission tomography. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. https://doi.org/10.1002/alz.13164
12. Wang, D., Honnorat, N., Fox, P. T., Ritter, K., Eickhoff, S. B., Seshadri, S., Alzheimer’s Disease Neuroimaging Initiative, & Habes, M. (2023). Deep neural network heatmaps capture Alzheimer’s disease patterns reported in a large meta-analysis of neuroimaging studies. NeuroImage, 269, 119929. https://doi.org/10.1016/j.neuroimage.2023.119929
13. Wortha, S. M., Frenzel, S., Bahls, M., Habes, M., Wittfeld, K., Van der Auwera, S., Bülow, R., Zylla, S., Friedrich, N., Nauck, M., Völzke, H., Grabe, H. J., Schwarz, C., & Flöel, A. (2023). Association of spermidine plasma levels with brain aging in a population-based study. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 19(5), 1832–1840. https://doi.org/10.1002/alz.12815
14. Younes, K., & Mormino, E. C. (2023). The pathotome and precision health. Brain: A Journal of Neurology, 146(6), 2208–2210. https://doi.org/10.1093/brain/awad154
15. Archer DB, Eissman JM, Mukherjee S, Lee ML, Choi S, Scollard P, Trittschuh EH, Mez JB, Bush WS, Kunkle BW, Naj AC, Gifford KA, The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimer’s Disease Genetics Consortium (ADGC), The Alzheimer’s Disease Sequencing Project (ADSP), Cuccaro ML, Pericak-Vance MA, Farrer LA, Wang L, Schellenberg GD, Mayeux RP, Haines JL, Jefferson AL, Kukull WA, Keene C, Saykin AJ, Thompson PA, Martin ER, Bennett DA, Barnes LL, Schneider JA, Crane PK, Dumitrescu L, Hohman TJ (2023). Longitudinal change in memory performance as a strong endophenotype for Alzheimer’s disease. Alzheimer’s & Dementia. PMC in process.
16. Eissman JM, Mukherjee S, Lee ML, Choi S, Scollard P, Trittschuh EH, Mez JB, Bush WS, Kunkle BW, Naj AC, Gifford KA, The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimer’s Disease Genetics Consortium (ADGC), The Alzheimer’s Disease Sequencing Project (ADSP), Cuccaro ML, Cruchaga C, Pericak-Vance MA, Farrer LA, Wang L, Schellenberg GD, Mayeux RP, Haines JL, Jefferson AL, Kukull WA, Keene C, Saykin AJ, Thompson PA, Martin ER, Bennett DA, Barnes LL, Schneider JA, Crane PK, Hohman TJ, Dumitrescu L (2023). Sex-specific genetic architecture of late-life memory performance. Alzheimer’s & Dementia. PMC in Process.